应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BK1593 医美概念股
已收盘 11-16 16:00:00
820.606
-9.771
-1.18%
最高
835.301
最低
807.487
成交量
4,850万
今开
830.160
昨收
830.376
日振幅
3.35%
总市值
0.00
流通市值
0.00
总股本
0.00
成交额
4.13亿
换手率
--
流通股本
0.00
市净率
1.083678
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
复星医药(02196): FXR0906 注射液用于治疗高甘油三酯血症于中国境内启动 II 期临床试验
智通财经 · 18:03
复星医药(02196): FXR0906 注射液用于治疗高甘油三酯血症于中国境内启动 II 期临床试验
昊海生物科技(06826)11月16日斥资约139.15万港元回购8.86万股
智通财经 · 17:41
昊海生物科技(06826)11月16日斥资约139.15万港元回购8.86万股
复星医药(600196.SH)控股子公司药品SRT-003-1获临床试验批准
智通财经 · 17:10
复星医药(600196.SH)控股子公司药品SRT-003-1获临床试验批准
复星医药:控股子公司药品HLX105获临床试验批准
格隆汇 · 16:47
复星医药:控股子公司药品HLX105获临床试验批准
四环医药(00460.HK):轩竹生物(02575.HK)吡洛西利新增适应症纳入2026年国家基本医保药品目录
智通财经 · 16:42
四环医药(00460.HK):轩竹生物(02575.HK)吡洛西利新增适应症纳入2026年国家基本医保药品目录
瑞银:国家医保目录谈判成功率维持高位 1类创新药创新高
智通财经 · 16:01
瑞银:国家医保目录谈判成功率维持高位 1类创新药创新高
复星医药:多款药品新纳入国家医保目录
格隆汇 · 11-15 16:02
复星医药:多款药品新纳入国家医保目录
瑞丽口岸前10个月进出口货值稳步增长
市场资讯 · 11-13
瑞丽口岸前10个月进出口货值稳步增长
复星医药(02196)11月13日斥资2458.98万港元回购148.55万股
智通财经 · 11-13
复星医药(02196)11月13日斥资2458.98万港元回购148.55万股
复星医药:计划回购H股不超过港币10亿元
证券之星 · 11-13
复星医药:计划回购H股不超过港币10亿元
复星医药:二级市场股价受公司经营、行业发展、市场情绪、宏观环境等多重因素影响
证券之星 · 11-13
复星医药:二级市场股价受公司经营、行业发展、市场情绪、宏观环境等多重因素影响
股市必读:复星医药新发布《复星医药关于控股子公司药品临床试验进展的公告》
证券之星 · 11-13
股市必读:复星医药新发布《复星医药关于控股子公司药品临床试验进展的公告》
复星医药(02196.HK):FKC516注射液用于复发或难治B 细胞非霍奇金淋巴瘤(r/rB-NHL)于中国境内1启动II期临床试验
智通财经 · 11-12
复星医药(02196.HK):FKC516注射液用于复发或难治B 细胞非霍奇金淋巴瘤(r/rB-NHL)于中国境内1启动II期临床试验
复星医药最新公告:控股子公司FKC516注射液启动II期临床试验
证券之星 · 11-12
复星医药最新公告:控股子公司FKC516注射液启动II期临床试验
复星医药(600196)11月11日主力资金净卖出597.22万元
证券之星 · 11-12
复星医药(600196)11月11日主力资金净卖出597.22万元
复锐医疗科技(01696.HK)11月11日耗资约4.68万港元回购2.52万股
智通财经 · 11-11
复锐医疗科技(01696.HK)11月11日耗资约4.68万港元回购2.52万股
港股异动 | 完美医疗(01830.HK)再涨超6% 预期中期纯利最高同比增加约55%
智通财经 · 11-11
港股异动 | 完美医疗(01830.HK)再涨超6% 预期中期纯利最高同比增加约55%
港股异动 | 完美医疗(01830)再涨超6% 预期中期纯利最高同比增加约55%
智通财经 · 11-11
港股异动 | 完美医疗(01830)再涨超6% 预期中期纯利最高同比增加约55%
复锐医疗科技(01696)11月10日耗资约3.27万港元回购1.8万股
智通财经 · 11-10
复锐医疗科技(01696)11月10日耗资约3.27万港元回购1.8万股
港股异动 | 完美医疗(01830.HK)盈喜后涨超22% 预期中期纯利同比增加约50%至55%
智通财经 · 11-10
港股异动 | 完美医疗(01830.HK)盈喜后涨超22% 预期中期纯利同比增加约50%至55%
加载更多
公司概况
公司名称:
BK1593
所属市场:
上市日期:
--
主营业务:
发行价格:
--
{"stockData":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"医美概念股","latestPrice":820.6059,"timestamp":1794816491594,"preClose":830.37646,"halted":0,"volume":48495100,"delay":0,"changeRate":-0.011766,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-9.770569,"latestTime":"11-16 16:00:00","open":830.16046,"high":835.3012,"low":807.4871,"amount":413150270,"amplitude":0.033496,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794879000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1794792600000,1794801600000],[1794805200000,1794816000000]],"pbRate":1.083678,"peRate":9.951087,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1593","defaultTab":"news","newsList":[{"id":"2683690977","title":"复星医药(02196): FXR0906 注射液用于治疗高甘油三酯血症于中国境内启动 II 期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2683690977","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683690977?lang=zh_cn&edition=full","pubTime":"2026-11-16 18:03","pubTimestamp":1794823397,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(02196)公布,近日,公司控股子公司复星医药产业发展(深圳)有限公司就 FXR0906 注射液用于治疗高甘油三酯血症于中国境内启动 II 期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","MDTX","BK0012","BK0188","PSYK","BK1191","BK0175","BK0028","BK0183","BK1593","BMED","BK0096","IBBJ","BK0239","02196","BK0187","600196","BK1515","IBBQ","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683697120","title":"昊海生物科技(06826)11月16日斥资约139.15万港元回购8.86万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2683697120","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683697120?lang=zh_cn&edition=full","pubTime":"2026-11-16 17:41","pubTimestamp":1794822102,"startTime":"0","endTime":"0","summary":"智通财经APP讯,昊海生物科技(06826)发布公告,于2026年11月16日该公司斥资约139.15万港元回购8.86万股,回购价格为每股15.38至15.82港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1161","06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683870692","title":"复星医药(600196.SH)控股子公司药品SRT-003-1获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2683870692","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683870692?lang=zh_cn&edition=full","pubTime":"2026-11-16 17:10","pubTimestamp":1794820205,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药 发布公告,近日,公司控股子公司成都星睿菁烜生物科技有限公司收到国家药品监督管理局关于同意[ 18F]F-SR031 注射液用于实体瘤患者成纤维细胞活化蛋白阳性病灶正电子发射断层扫描显像的临床试验批准。星睿菁烜拟于条件具备后于中国境内开展该药品的 I 期临床研究。以氟[ 18F]标记的FAP抑制剂可与 CAF 表面的 FAP 特异性结合,使 FAP 高表达的肿瘤病灶在PET 显像中呈高摄取,从而用于肿瘤的诊断、分期及疗效评估。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BMED","BK0239","BK0028","BK0096","BK1593","02196","BK0175","BK1191","BK0187","PSYK","IBBJ","MDTX","BK0196","BK0060","BK0012","600196","BK0188","BK0183","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683869178","title":"复星医药:控股子公司药品HLX105获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2683869178","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683869178?lang=zh_cn&edition=full","pubTime":"2026-11-16 16:47","pubTimestamp":1794818861,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","BK1191","BK0012","BK1515","BK0060","02196","BK1593","600196","BK0175","BK0187","BK0096","BK0196","BK0188","BK0028","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683288691","title":"四环医药(00460.HK):轩竹生物(02575.HK)吡洛西利新增适应症纳入2026年国家基本医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2683288691","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683288691?lang=zh_cn&edition=full","pubTime":"2026-11-16 16:42","pubTimestamp":1794818543,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1600","BK1191","00460","BK1515","02575","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683699366","title":"瑞银:国家医保目录谈判成功率维持高位 1类创新药创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2683699366","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683699366?lang=zh_cn&edition=full","pubTime":"2026-11-16 16:01","pubTimestamp":1794816106,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,瑞银发布研报称,国家医保局公布2026年国家医保药品目录及商业保险创新药目录,在124个经审查的谈判或竞价候选药品中,107个获纳入医保目录,另有34个因临床替代及供应等因素被调出,令医保目录涵盖药品总数增至3,331个,同比增长2.4%,国家医保目录谈判成功率维持高位。该行指出,107个新纳入药品中有51个为1类创新药,占新增药品总数近一半,创历史新高;商业保险创新药目录的12个谈判药品亦全部获纳入。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523605.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226288170.HKD","HK0000165453.HKD","LU1960683339.HKD","LNGR","01530","LU1152091754.HKD","LU1813983027.USD","LU1226287529.USD","IE00BZ08YT58.USD","LU1328277881.USD","LU1951186391.HKD","LU0067412154.USD","LU0314109678.HKD","LU1226288253.USD","IBBQ","BK1574","LU0501845795.SGD","06978","BK1521","BK1589","LU0326950275.SGD","LU1152091168.USD","03692","BK1515","IE00B543WZ88.USD","159992","LU0140636845.USD","MEDX","LU1008478684.HKD","SG9999004220.SGD","LU1226287875.USD","IE00B5MMRT66.SGD","BK1191","IE0008369823.USD","01093","BK1593","IE00BZ08YS42.EUR","LU0880133367.SGD","01177","KURE","LU0315179316.USD","BK1583","IE00BZ08YR35.GBP","IE0008368742.USD","LU1226287792.SGD","02096","LU2039709279.SGD","LU0072913022.USD","BK1161","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683655437","title":"复星医药:多款药品新纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2683655437","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683655437?lang=zh_cn&edition=full","pubTime":"2026-11-15 16:02","pubTimestamp":1794729757,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","BK0187","BK0188","BK1515","02196","BK0239","BK0012","BK0196","600196","BK1593","BK0175","BK0096","BK0183","BK1191","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683574488","title":"瑞丽口岸前10个月进出口货值稳步增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2683574488","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683574488?lang=zh_cn&edition=full","pubTime":"2026-11-13 18:04","pubTimestamp":1794564240,"startTime":"0","endTime":"0","summary":"(来源:德宏发布)记者昨天从瑞丽海关获悉,今年前10个月,经瑞丽口岸进出口货值594.5亿元,同比增长13.7%,其中进口货值570.1亿元,出口货值24.4亿元。进口方面,能源产品货值增长9.9%,玉石毛料及其制品进口2亿元。出口以机电产品、劳动密集型产品为主,其中机电产品出口9.2亿元。来源:央视影音客户端编辑 丨周 勇审核丨周 舟 陈子鸥","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-11-13/doc-iniyqwtx1178911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1209","BK1593","02135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683798375","title":"复星医药(02196)11月13日斥资2458.98万港元回购148.55万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2683798375","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683798375?lang=zh_cn&edition=full","pubTime":"2026-11-13 17:45","pubTimestamp":1794563144,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(02196)发布公告,于2026年11月13日斥资2458.98万港元回购148.55万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1522974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0060","BK0028","BK0175","BK0187","BK0188","BK0196","BK0239","BK1191","02196","BK1593","BK0096","BK0183","600196","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683576050","title":"复星医药:计划回购H股不超过港币10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2683576050","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683576050?lang=zh_cn&edition=full","pubTime":"2026-11-13 17:39","pubTimestamp":1794562768,"startTime":"0","endTime":"0","summary":"证券之星消息,复星医药(600196)11月13日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司有考虑增持回购计划吗?谢谢复星医药回复:投资者您好!经董事会批准,公司计划自2026年8月27日起12个月内、以不超过港币10亿元的总金额回购公司H股,回购股份的用途包括但不限于依法注销或作为库存股持有。截至11月13日收市,公司已根据前述回购方案累计回购1,945.40万股H股,累计回购金额约为港币3.28亿元。公司将根据市场情况、股价表现及相关规则,推进上述回购计划。感谢您对公司的关注。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300031294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0187","BK0196","BK0239","BK0183","BK1191","600196","BK1515","BK0096","BK1593","BK0188","BK0012","02196","BK0028","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683457609","title":"复星医药:二级市场股价受公司经营、行业发展、市场情绪、宏观环境等多重因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2683457609","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683457609?lang=zh_cn&edition=full","pubTime":"2026-11-13 17:39","pubTimestamp":1794562749,"startTime":"0","endTime":"0","summary":"证券之星消息,复星医药(600196)11月13日在投资者关系平台上答复投资者关心的问题。投资者提问:问公司管理层股价、成交量长期低迷,投资几年一直亏损。你们拿什么回报投资者?对得起中小投资者吗?复星医药回复:投资者您好!二级市场股价受公司经营、行业发展、市场情绪、宏观环境等多重因素影响。公司将持续提升经营质量,努力以更好的经营成果回报投资者。感谢您长期以来的关注与支持。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300031273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","BK0196","02196","BK0239","BK1593","BK1191","BK0183","BK0188","BK0187","BK1515","BK0060","BK0096","BK0028","BK0012","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683198315","title":"股市必读:复星医药新发布《复星医药关于控股子公司药品临床试验进展的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2683198315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683198315?lang=zh_cn&edition=full","pubTime":"2026-11-13 01:45","pubTimestamp":1794505513,"startTime":"0","endTime":"0","summary":"截至2026年11月12日收盘,复星医药报收于22.81元,下跌0.48%,换手率0.6%,成交量12.64万手,成交额2.88亿元。公司公告汇总:复星医药控股子公司就FKC516注射液在中国境内启动针对复发或难治B细胞非霍奇金淋巴瘤的II期临床试验。FKC516为复星医药许可引进的靶向CD20自体CAR-T细胞治疗产品,复星医药拥有其全球范围全疾病领域的开发和商业化独占权利。FKC516仍需完成临床试验并经国家药品审评部门批准后方可上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300002063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02196","BK0187","BK1593","BK0012","BK0060","BK0239","BK1191","600196","BK1515","BK0183","BK0188","BK0096","BK0196","BK0028","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682561320","title":"复星医药(02196.HK):FKC516注射液用于复发或难治B 细胞非霍奇金淋巴瘤(r/rB-NHL)于中国境内1启动II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2682561320","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682561320?lang=zh_cn&edition=full","pubTime":"2026-11-12 18:10","pubTimestamp":1794478257,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1191","BK1515","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682566132","title":"复星医药最新公告:控股子公司FKC516注射液启动II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2682566132","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682566132?lang=zh_cn&edition=full","pubTime":"2026-11-12 17:33","pubTimestamp":1794476012,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称,公司控股子公司复星凯瑞就FKC516注射液用于复发或难治B细胞非霍奇金淋巴瘤于中国境内启动II期临床试验。FKC516为靶向CD20自体CAR-T细胞治疗产品,截至2026年9月累计研发投入约1337万元。目前中国境内尚无同靶点CAR-T产品获批上市。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111200031109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0183","BK0196","BK0060","BK1515","BK1593","BK0096","BK0187","BK1191","02196","BK0012","BK0175","BK0188","BK0028","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682824536","title":"复星医药(600196)11月11日主力资金净卖出597.22万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682824536","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682824536?lang=zh_cn&edition=full","pubTime":"2026-11-12 08:27","pubTimestamp":1794443250,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月11日收盘,复星医药报收于22.92元,下跌2.05%,换手率0.69%,成交量14.66万手,成交额3.37亿元。近5日资金流向一览见下表:复星医药融资融券信息显示,融资方面,当日融资买入3793.77万元,融资偿还1996.36万元,融资净买入1797.41万元,连续3日净买入累计3987.27万元。复星医药主营业务:制药、医疗器械与医学诊断、医疗健康服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111200006496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0187","BK0188","BK1515","02196","BK0239","BK0012","BK0196","600196","BK1593","BK0175","BK0096","BK0183","BK1191","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682305524","title":"复锐医疗科技(01696.HK)11月11日耗资约4.68万港元回购2.52万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2682305524","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682305524?lang=zh_cn&edition=full","pubTime":"2026-11-11 19:07","pubTimestamp":1794395227,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01696","BK1100","BK1585","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682320362","title":"港股异动 | 完美医疗(01830.HK)再涨超6% 预期中期纯利最高同比增加约55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682320362","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682320362?lang=zh_cn&edition=full","pubTime":"2026-11-11 14:02","pubTimestamp":1794376939,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1215","01830","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682320360","title":"港股异动 | 完美医疗(01830)再涨超6% 预期中期纯利最高同比增加约55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682320360","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682320360?lang=zh_cn&edition=full","pubTime":"2026-11-11 14:02","pubTimestamp":1794376939,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,完美医疗(01830)再涨超6%,高见1.59港元创去年6月以来新高。截至发稿,涨6.71%,报1.59港元,成交额364.11万港元。消息面上,完美医疗日前发布盈利预告,根据管理层对截至2026年9月30日止六个月未经审核综合管理账目的初步评估,预期本期间股东应占溢利约为1.42亿港元至1.47亿港元,同比增加约50%至55%。主要由于数码转型释放成本效益及可扩展性、精简网络带来更强经营杠杆,以及澳洲、新加坡及澳门业务逐步回稳并展现改善动能。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1521529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01830","BK4585","BK1593","BK4588","KCAI","BK1215","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682839648","title":"复锐医疗科技(01696)11月10日耗资约3.27万港元回购1.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2682839648","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682839648?lang=zh_cn&edition=full","pubTime":"2026-11-10 18:58","pubTimestamp":1794308330,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复锐医疗科技(01696)公布,2026年11月10日耗资约3.27万港元回购1.8万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1521209.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01696","BK1593","BK1585","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682835699","title":"港股异动 | 完美医疗(01830.HK)盈喜后涨超22% 预期中期纯利同比增加约50%至55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682835699","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682835699?lang=zh_cn&edition=full","pubTime":"2026-11-10 09:44","pubTimestamp":1794275091,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","01830","BK1215"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0345},{"period":"1month","weight":-0.0278},{"period":"3month","weight":-0.0589},{"period":"6month","weight":-0.0896},{"period":"1year","weight":-0.1269},{"period":"ytd","weight":-0.0778}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1593","nameEN":"BK1593"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医美概念股,BK1593,医美概念股股票,医美概念股股票老虎,医美概念股股票老虎国际,医美概念股行情,医美概念股股票行情,医美概念股股价,医美概念股股市,医美概念股股票价格,医美概念股股票交易,医美概念股股票购买,医美概念股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}